Stock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition

Stock Track04:33

Neurocrine Biosciences' stock surged 8.85% in after-hours trading on Tuesday, following the release of its first-quarter 2026 financial results.

The biopharmaceutical company reported adjusted earnings per share of $1.94, significantly beating the analyst consensus estimate of $1.15. Quarterly revenue reached approximately $811 million, representing a 44% year-over-year increase and surpassing expectations. The strong performance was driven by double-digit prescription volume growth for its drug INGREZZA and robust patient demand for CRENESSITY.

Additionally, Neurocrine announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move expected to close in the second quarter of 2026. The company also reaffirmed its full-year 2026 sales guidance for INGREZZA, projecting $2.7 billion to $2.8 billion in net sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182457826?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182457826","market":"us","top_or_hot":-1,"title":"Stock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition","media":"Stock Track","content":"<p>Neurocrine Biosciences' stock surged 8.85% in after-hours trading on Tuesday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported adjusted earnings per share of $1.94, significantly beating the analyst consensus estimate of $1.15. Quarterly revenue reached approximately $811 million, representing a 44% year-over-year increase and surpassing expectations. The strong performance was driven by double-digit prescription volume growth for its drug INGREZZA and robust patient demand for CRENESSITY.</p><p>Additionally, Neurocrine announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move expected to close in the second quarter of 2026. The company also reaffirmed its full-year 2026 sales guidance for INGREZZA, projecting $2.7 billion to $2.8 billion in net sales.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Neurocrine Biosciences Soars 8.85% After-Hours on Strong Q1 Earnings Beat and $2.9B Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 04:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Neurocrine Biosciences' stock surged 8.85% in after-hours trading on Tuesday, following the release of its first-quarter 2026 financial results.</p><p>The biopharmaceutical company reported adjusted earnings per share of $1.94, significantly beating the analyst consensus estimate of $1.15. Quarterly revenue reached approximately $811 million, representing a 44% year-over-year increase and surpassing expectations. The strong performance was driven by double-digit prescription volume growth for its drug INGREZZA and robust patient demand for CRENESSITY.</p><p>Additionally, Neurocrine announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move expected to close in the second quarter of 2026. The company also reaffirmed its full-year 2026 sales guidance for INGREZZA, projecting $2.7 billion to $2.8 billion in net sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"","article_id":"1182457826","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182457826","pubTimestamp":1778013234,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Neurocrine Biosciences' stock surged 8.85% in after-hours trading on Tuesday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学"},"translate_title":"股票追踪|Neurocrine Biosciences盘后飙升8.85%，因第一季度盈利强劲增长和2.9 B美元收购","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1},"content_text":"Neurocrine Biosciences' stock surged 8.85% in after-hours trading on Tuesday, following the release of its first-quarter 2026 financial results.The biopharmaceutical company reported adjusted earnings per share of $1.94, significantly beating the analyst consensus estimate of $1.15. Quarterly revenue reached approximately $811 million, representing a 44% year-over-year increase and surpassing expectations. The strong performance was driven by double-digit prescription volume growth for its drug INGREZZA and robust patient demand for CRENESSITY.Additionally, Neurocrine announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, a strategic move expected to close in the second quarter of 2026. The company also reaffirmed its full-year 2026 sales guidance for INGREZZA, projecting $2.7 billion to $2.8 billion in net sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182457826","isCrawlerRequest":true}